BACKGROUND: Bilirubin is a product of heme oxygenase and an antioxidant per se. In selected cohorts and patient studies, bilirubin was associated with decreased risk for cardiovascular events. We aimed to determine the association of serum bilirubin with coronary artery calcification (CAC) and incident cardiovascular disease in the unselected general population. METHODS: Participants without prior coronary heart or liver disease were drawn from the population-based Heinz Nixdorf Recall study. CAC was measured from electron beam computed tomography and quantified using the Agatston method. Incident major cardiovascular events (coronary events, stroke, cardiovascular death) were assessed during follow-up. The association of bilirubin with CAC score and incident events was calculated using regression analysis. RESULTS: A total of 3,553 subjects (mean age 59.4 years, 44 % male) were included. Bilirubin was inversely correlated with CAC in men [estimated % change in (CAC + 1) per each gender-specific standard deviation of bilirubin [95 % confidence interval (CI): -6.1 (-11.6; -1.7) %, p = 0.032] but less so in women [-3.6 (-7.7; 0.2) %, p = 0.065], when adjusting for age only. With adjustment for traditional cardiovascular risk factors, the association was less pronounced [men: -2.5 (-7.5; 2.6) %, p = 0.35, women: -0.2 (-4.1; 3.5) %, p = 0.9]. Likewise, higher bilirubin by one standard deviation was associated with 19 % lower frequency of incident cardiovascular events in age- and gender-adjusted Cox regression analysis [hazard ratio (95 % CI): 0.81 (0.68; 0.96), p = 0.014]; this effect was slightly attenuated after adjustment for traditional cardiovascular risk factors [0.87 (0.73; 1.04), p = 0.13]. CONCLUSION: Our data from a general population suggest that a potential protective role of bilirubin in the atherosclerosis process is largely secondary to a more beneficial risk factor profile.
BACKGROUND:Bilirubin is a product of heme oxygenase and an antioxidant per se. In selected cohorts and patient studies, bilirubin was associated with decreased risk for cardiovascular events. We aimed to determine the association of serum bilirubin with coronary artery calcification (CAC) and incident cardiovascular disease in the unselected general population. METHODS:Participants without prior coronary heart or liver disease were drawn from the population-based Heinz Nixdorf Recall study. CAC was measured from electron beam computed tomography and quantified using the Agatston method. Incident major cardiovascular events (coronary events, stroke, cardiovascular death) were assessed during follow-up. The association of bilirubin with CAC score and incident events was calculated using regression analysis. RESULTS: A total of 3,553 subjects (mean age 59.4 years, 44 % male) were included. Bilirubin was inversely correlated with CAC in men [estimated % change in (CAC + 1) per each gender-specific standard deviation of bilirubin [95 % confidence interval (CI): -6.1 (-11.6; -1.7) %, p = 0.032] but less so in women [-3.6 (-7.7; 0.2) %, p = 0.065], when adjusting for age only. With adjustment for traditional cardiovascular risk factors, the association was less pronounced [men: -2.5 (-7.5; 2.6) %, p = 0.35, women: -0.2 (-4.1; 3.5) %, p = 0.9]. Likewise, higher bilirubin by one standard deviation was associated with 19 % lower frequency of incident cardiovascular events in age- and gender-adjusted Cox regression analysis [hazard ratio (95 % CI): 0.81 (0.68; 0.96), p = 0.014]; this effect was slightly attenuated after adjustment for traditional cardiovascular risk factors [0.87 (0.73; 1.04), p = 0.13]. CONCLUSION: Our data from a general population suggest that a potential protective role of bilirubin in the atherosclerosis process is largely secondary to a more beneficial risk factor profile.
Authors: Thomas Jansen; Marcus Hortmann; Matthias Oelze; Benjamin Opitz; Sebastian Steven; Richard Schell; Maike Knorr; Susanne Karbach; Swenja Schuhmacher; Philip Wenzel; Thomas Münzel; Andreas Daiber Journal: J Mol Cell Cardiol Date: 2010-04-27 Impact factor: 5.000
Authors: Kim Ekblom; Stefan L Marklund; Lars Johansson; Pia Osterman; Göran Hallmans; Lars Weinehall; Per-Gunnar Wiklund; Johan Hultdin Journal: Cerebrovasc Dis Date: 2010-10-16 Impact factor: 2.762
Authors: Raimund Erbel; Stefan Möhlenkamp; Susanne Moebus; Axel Schmermund; Nils Lehmann; Andreas Stang; Nico Dragano; Dietrich Grönemeyer; Rainer Seibel; Hagen Kälsch; Martina Bröcker-Preuss; Klaus Mann; Johannes Siegrist; Karl-Heinz Jöckel Journal: J Am Coll Cardiol Date: 2010-10-19 Impact factor: 24.094
Authors: Axel Schmermund; Nils Lehmann; Lawrence F Bielak; PanFong Yu; Patrick F Sheedy; Andrea E Cassidy-Bushrow; Stephen T Turner; Susanne Moebus; Stefan Möhlenkamp; Andreas Stang; Klaus Mann; Karl-Heinz Jöckel; Raimund Erbel; Patricia A Peyser Journal: Atherosclerosis Date: 2007-05-29 Impact factor: 5.162
Authors: Sehoon Park; Do Hyoung Kim; Jin Ho Hwang; Yong-Chul Kim; Jin Hyuk Kim; Chun Soo Lim; Yon Su Kim; Seung Hee Yang; Jung Pyo Lee Journal: PLoS One Date: 2017-02-22 Impact factor: 3.240